Barrenetxea G, Martin-Mateos M, Barzazan M J, Montoya F, Matia J C, Rodriguez-Escudero F J
Gynecologic Oncology Department, Hospital de Cruces, Bilbao, Spain.
Eur J Gynaecol Oncol. 1990;11(5):369-74.
Sera from 52 ovarian cancer patients undergoing chemotherapy and second look operation were studied. CA 125, CA 15.3 and CA 19.9 assays were performed during chemotherapy and prior to relaparotomy. Twenty-six patients (50%) had no evidence of disease whereas 2 (3.8%) and 24 (46.1%) had microscopic and macroscopic disease. In general although the predictive value of an elevated CA 125 or CA 15.3 level is excellent, a normal value (less than 35 U/ml) has limited significance. Moreover, we found no improvement in negative predictive and positive predictive value by adding the determination of CA 19.9.
对52例接受化疗并进行二次探查手术的卵巢癌患者的血清进行了研究。在化疗期间和再次剖腹手术前进行了CA 125、CA 15.3和CA 19.9检测。26例患者（50%）无疾病证据，而2例（3.8%）和24例（46.1%）有微小和肉眼可见的疾病。总体而言，尽管CA 125或CA 15.3水平升高的预测价值极佳，但正常数值（低于35 U/ml）的意义有限。此外，我们发现增加CA 19.9检测并未提高阴性预测值和阳性预测值。
